GEP20125650B - Thiophene or thiazole derivatives and use thereof as pi3k inhibitors - Google Patents

Thiophene or thiazole derivatives and use thereof as pi3k inhibitors

Info

Publication number
GEP20125650B
GEP20125650B GEAP200912065A GEAP2009012065A GEP20125650B GE P20125650 B GEP20125650 B GE P20125650B GE AP200912065 A GEAP200912065 A GE AP200912065A GE AP2009012065 A GEAP2009012065 A GE AP2009012065A GE P20125650 B GEP20125650 B GE P20125650B
Authority
GE
Georgia
Prior art keywords
thiophene
pi3k inhibitors
thiazole derivatives
pi3k
proliferative
Prior art date
Application number
GEAP200912065A
Other languages
English (en)
Inventor
David P Cardin
Jeffrey L Gaulin
Paul D Greenspan
Stepan Vyskocil
Tianlin Xu
Christelle C Renou
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41010579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20125650(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of GEP20125650B publication Critical patent/GEP20125650B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GEAP200912065A 2008-06-19 2009-06-17 Thiophene or thiazole derivatives and use thereof as pi3k inhibitors GEP20125650B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13248408P 2008-06-19 2008-06-19

Publications (1)

Publication Number Publication Date
GEP20125650B true GEP20125650B (en) 2012-09-25

Family

ID=41010579

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP200912065A GEP20125650B (en) 2008-06-19 2009-06-17 Thiophene or thiazole derivatives and use thereof as pi3k inhibitors

Country Status (21)

Country Link
US (3) US8183240B2 (enExample)
EP (1) EP2313399B1 (enExample)
JP (1) JP5596026B2 (enExample)
KR (1) KR20110018451A (enExample)
CN (1) CN102066365A (enExample)
AU (1) AU2009260782B2 (enExample)
BR (1) BRPI0914223A2 (enExample)
CA (1) CA2727069A1 (enExample)
CL (1) CL2010001474A1 (enExample)
CO (1) CO6331431A2 (enExample)
CR (1) CR20110032A (enExample)
EA (1) EA201170052A1 (enExample)
ES (1) ES2491522T3 (enExample)
GE (1) GEP20125650B (enExample)
IL (1) IL210055A0 (enExample)
MA (1) MA32468B1 (enExample)
MX (1) MX2010014125A (enExample)
NZ (1) NZ589844A (enExample)
UA (1) UA106206C2 (enExample)
WO (1) WO2009154741A1 (enExample)
ZA (1) ZA201008875B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
ES2491522T3 (es) * 2008-06-19 2014-09-08 Millennium Pharmaceuticals, Inc. Derivados de tiofeno o tiazol y su uso como inhibidores de PI3K
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2012516329A (ja) * 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用
EP2603216A4 (en) * 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
WO2012021696A1 (en) * 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021611A1 (en) * 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP5726635B2 (ja) 2010-08-25 2015-06-03 株式会社Ｎｔｔドコモ マルチモードフロントエンド回路
CA2814688A1 (en) 2010-10-13 2012-04-19 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102503930B (zh) * 2011-10-28 2014-07-02 浙江大学 3,4,5,-三取代氨基噻吩类化合物及其制备和用途
EP2790705B1 (en) 2011-12-15 2017-12-06 Novartis AG Use of inhibitors of the activity or function of pi3k
JP2015503505A (ja) * 2011-12-23 2015-02-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヘテロアリールおよびその使用
CN104204805B (zh) 2012-03-14 2017-08-01 萨克生物研究学院 腺病毒肿瘤诊断法
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
KR20150130451A (ko) 2013-03-15 2015-11-23 제넨테크, 인크. 암 치료 방법 및 항암제 내성 예방을 위한 방법
CN106164071B (zh) * 2014-02-14 2019-09-10 不列颠哥伦比亚大学 作为治疗剂的人雄激素受体dna-结合结构域(dbd)化合物及其使用方法
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
CA3144848C (en) * 2019-06-28 2023-11-21 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
CN110759900B (zh) * 2019-10-25 2021-07-30 沈阳药科大学 噻吩类化合物的制备方法和用途
EP4077302A1 (en) 2019-12-20 2022-10-26 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof
CN113527281B (zh) * 2020-04-20 2023-12-22 昆山彭济凯丰生物科技有限公司 杂环化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD275870A1 (de) 1988-09-27 1990-02-07 Univ Leipzig Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen
EP1742627A4 (en) 2004-05-06 2009-08-26 Plexxikon Inc PDE4B HEMMER AND ITS USE
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
US20090076009A1 (en) * 2006-05-03 2009-03-19 Arnould Jean-Claude Retired Thiazole derivatives and their use as anti-tumour agents
CA2660758A1 (en) * 2006-08-24 2008-02-27 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CA2704711C (en) * 2007-09-24 2016-07-05 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
ES2491522T3 (es) * 2008-06-19 2014-09-08 Millennium Pharmaceuticals, Inc. Derivados de tiofeno o tiazol y su uso como inhibidores de PI3K

Also Published As

Publication number Publication date
NZ589844A (en) 2012-11-30
UA106206C2 (ru) 2014-08-11
EP2313399A1 (en) 2011-04-27
EP2313399B1 (en) 2014-05-28
WO2009154741A8 (en) 2010-03-25
MX2010014125A (es) 2011-02-24
JP5596026B2 (ja) 2014-09-24
CL2010001474A1 (es) 2011-04-29
BRPI0914223A2 (pt) 2019-09-24
EA201170052A1 (ru) 2011-06-30
JP2011524904A (ja) 2011-09-08
CN102066365A (zh) 2011-05-18
CA2727069A1 (en) 2009-12-23
MA32468B1 (fr) 2011-07-03
WO2009154741A1 (en) 2009-12-23
IL210055A0 (en) 2011-02-28
CR20110032A (es) 2011-03-14
AU2009260782A1 (en) 2009-12-23
US20130217689A1 (en) 2013-08-22
US20100075951A1 (en) 2010-03-25
AU2009260782B2 (en) 2014-12-11
ZA201008875B (en) 2012-02-29
CO6331431A2 (es) 2011-10-20
US8440664B2 (en) 2013-05-14
ES2491522T3 (es) 2014-09-08
KR20110018451A (ko) 2011-02-23
US8183240B2 (en) 2012-05-22
US20120202812A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
GEP20125650B (en) Thiophene or thiazole derivatives and use thereof as pi3k inhibitors
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
WO2010003475A3 (de) Neue pyrrolidinderivate als metap-2 inhibitoren
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
IN2012DN01233A (enExample)
MX336381B (es) Boronatos como inhibidores de arginasa.
GEP20146033B (en) N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides usage as wnt signaling modulators
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
GEP20125635B (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
MY155695A (en) Quinoxalinedione derivatives
MX2010005824A (es) Derivados de aminotiazol.
TN2011000291A1 (en) Purine compounds
WO2010128050A3 (en) Dihydroorotate - dehydrogenasee inhibitors as virostatic compounds
IN2012DN03337A (enExample)
GEP20156241B (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
TN2010000038A1 (en) Organic compounds
GEP20156346B (en) Imidazole derivatives as pde10a enzyme inhibitors
UA99787C2 (en) Lactams as beta secretase inhibitors
NZ598750A (en) Therapeutic agent for mood disorders
MX2011012199A (es) Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
WO2011047055A3 (en) Novel mek inhibitors, useful in the treatment of diseases
NZ629898A (en) Compositions and methods for inhibition of cathepsins